Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GamTBvac in Healthy Adults
NCT03878004Phase 2Completed
- Start
- Dec 2018
- Primary completion
- Dec 2019
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of GamTBvac in Tuberculosis (TB) (2 arms). Primary endpoints: Level of IFN-y secretion in whole blood or PBMC fraction at Month 5 and Number of Participants With Adverse Events at Month 5. Started Dec 2018; status: completed.
02
Drugs
GamTBvac
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT03878004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03878004.